Healthcare

>

Drug Manufacturers—Specialty & Generic

>

OTC:
MEDIF

MEDIPHARM LABS CORP

Recent publications about $MEDIF

MediPharm Labs Sets Date to Report Second Quarter 2022 Financial Results

BARRIE, ON, Aug. 11, 2022 /PRNewswire/ – MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release second quarter financial results

MediPharm Labs Reports First Quarter Results

TORONTO, May 16, 2022 /PRNewswire/ – MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized

MediPharm Labs Sets Date to Report First Quarter 2022 Financial Results

TORONTO, May 12, 2022 /PRNewswire/ – MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three month period ended March 31, 2022 before markets open on Monday, May 16, 2022. MediPharm’s executive management team

Register by Email

or
Already a member? Sign In